RU2019120431A - Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ - Google Patents
Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ Download PDFInfo
- Publication number
- RU2019120431A RU2019120431A RU2019120431A RU2019120431A RU2019120431A RU 2019120431 A RU2019120431 A RU 2019120431A RU 2019120431 A RU2019120431 A RU 2019120431A RU 2019120431 A RU2019120431 A RU 2019120431A RU 2019120431 A RU2019120431 A RU 2019120431A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- disease
- alkyl
- pharmaceutically acceptable
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651706 | 2016-12-21 | ||
| SE1651706-2 | 2016-12-21 | ||
| PCT/GB2017/053868 WO2018115891A1 (en) | 2016-12-21 | 2017-12-21 | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019120431A true RU2019120431A (ru) | 2021-01-22 |
| RU2019120431A3 RU2019120431A3 (cg-RX-API-DMAC7.html) | 2021-03-09 |
Family
ID=60923799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019120431A RU2019120431A (ru) | 2016-12-21 | 2017-12-21 | Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200113910A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3558320A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020502225A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190098982A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110167558A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017380583A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019012709A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3046289A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267086A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019007606A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019120431A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018115891A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2816837C2 (ru) * | 2018-02-26 | 2024-04-05 | Алзекьюр Фарма Аб | Производные триазина для лечения заболеваний, связанных с нейротрофинами |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11352332B2 (en) | 2018-02-26 | 2022-06-07 | AlzeCure Pharma AB | Triazine derivatives for treating diseases relating to neurotrophins |
| GB201810668D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| GB201912404D0 (en) * | 2019-08-29 | 2019-10-16 | AlzeCure Pharma AB | New compounds |
| CN113057957A (zh) * | 2021-03-30 | 2021-07-02 | 福建中医药大学 | 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途 |
| CN113893334A (zh) * | 2021-10-19 | 2022-01-07 | 内蒙古医科大学第二附属医院 | 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2718799A1 (de) * | 1977-04-27 | 1978-11-09 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer |
| CA2765030C (en) * | 2009-06-09 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| WO2011070177A2 (en) * | 2009-12-11 | 2011-06-16 | Baltic Technology Development, Ltd. | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
-
2017
- 2017-12-21 EP EP17825283.9A patent/EP3558320A1/en not_active Withdrawn
- 2017-12-21 BR BR112019012709A patent/BR112019012709A2/pt not_active Application Discontinuation
- 2017-12-21 AU AU2017380583A patent/AU2017380583A1/en not_active Abandoned
- 2017-12-21 MX MX2019007606A patent/MX2019007606A/es unknown
- 2017-12-21 CA CA3046289A patent/CA3046289A1/en not_active Abandoned
- 2017-12-21 CN CN201780078675.XA patent/CN110167558A/zh active Pending
- 2017-12-21 KR KR1020197018642A patent/KR20190098982A/ko not_active Ceased
- 2017-12-21 RU RU2019120431A patent/RU2019120431A/ru not_active Application Discontinuation
- 2017-12-21 JP JP2019534090A patent/JP2020502225A/ja active Pending
- 2017-12-21 US US16/471,923 patent/US20200113910A1/en not_active Abandoned
- 2017-12-21 WO PCT/GB2017/053868 patent/WO2018115891A1/en not_active Ceased
-
2019
- 2019-06-04 IL IL267086A patent/IL267086A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2816837C2 (ru) * | 2018-02-26 | 2024-04-05 | Алзекьюр Фарма Аб | Производные триазина для лечения заболеваний, связанных с нейротрофинами |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019007606A (es) | 2020-07-29 |
| WO2018115891A1 (en) | 2018-06-28 |
| IL267086A (en) | 2019-08-29 |
| RU2019120431A3 (cg-RX-API-DMAC7.html) | 2021-03-09 |
| AU2017380583A1 (en) | 2019-06-27 |
| US20200113910A1 (en) | 2020-04-16 |
| CA3046289A1 (en) | 2018-06-28 |
| CN110167558A (zh) | 2019-08-23 |
| BR112019012709A2 (pt) | 2019-11-26 |
| JP2020502225A (ja) | 2020-01-23 |
| EP3558320A1 (en) | 2019-10-30 |
| KR20190098982A (ko) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6134046B1 (ja) | 医療で使用されるインドール誘導体 | |
| CN103119031B (zh) | 取代酰胺化合物 | |
| JP7330510B2 (ja) | 非滲出型または萎縮型の黄斑変性にて以前に失われた視力を回復させるための医薬組成物 | |
| JP2020502225A5 (cg-RX-API-DMAC7.html) | ||
| JP6837479B2 (ja) | 医薬化合物 | |
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| IL276624B2 (en) | Triazine derivatives for the treatment of neurotrophin-related diseases | |
| JP2016525104A5 (cg-RX-API-DMAC7.html) | ||
| CN1237168A (zh) | 双环芳基甲酰胺及其治疗应用 | |
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| CA3089952A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| US11779565B2 (en) | Small organic molecules for use in the treatment of neuroinflammatory disorders | |
| CN115028679A (zh) | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 | |
| MXPA06004483A (es) | Colinuro de 2-(3,4-dimetilfenil)-4-{[2-hidroxi-3'-(1h- tetrazol- 5- il)bifenil-3-il]hidrazono}-5 metil-2,4-dihidropirazol-3-ona. | |
| AU2017342240A1 (en) | Methods for treating ocular disease using inhibitors of CSF-1R | |
| JP6928479B2 (ja) | 拒絶反応抑制剤 | |
| WO2025011661A1 (zh) | 整合酶抑制类的制剂及其制备方法 | |
| JP2014509643A (ja) | 黄斑変性の予防または治療用の医薬組成物 | |
| KR101708764B1 (ko) | 중추신경계 질환의 치료 또는 예방용 약학 조성물 | |
| CN1125065C (zh) | 苯并[g]喹啉衍生物 | |
| JP6363192B2 (ja) | トリグリセリド、総コレステロール、及び低密度リポタンパク質の血中濃度を低減する方法 | |
| JP7836159B2 (ja) | 眼科用剤 | |
| JP2023544446A5 (cg-RX-API-DMAC7.html) | ||
| WO2006123675A1 (ja) | アミジノ誘導体を有効成分として含む神経細胞の保護剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220422 |